Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound ...

PwC analysts have warned the speedy evolution of the Chinese biotech sector is creating “heightened risks related to IP ...

All the figurative FDA trains are running on time, according to the agency’s leader Marty Makary, M.D. | “I'm proud to report ...

A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in ...

A pair of professional organizations in the U.K. is calling for the biopharma industry and national government to take action ...

Philips is rolling out what it describes as a next-generation point-of-care ultrasound system, designed specifically for ...

The FDA is introducing a new priority voucher program designed to shorten the drug review process from 10 to 12 months down to one or two months, according to the agency. | The FDA is introducing a ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...

Dexcom is working to replace some of the receivers that link with its continuous glucose monitoring systems due to a ...

Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around ...

The latest clinical win follows a dual set of phase 3 and phase 2 results back in March. In that data drop, Mineralys reported that lorundrostat reduced systolic blood pressure in a late-stage study ...